HLS Therapeutics (TSX:HLS) Shiller PE Ratio: (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:HLS HLS Therapeutics Inc TSX:HLS
69 GF Score
Price C$3.70
GF Value C$4.38
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


HLS Therapeutics  (TSX:HLS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


HLS Therapeutics Shiller PE Ratio Related Terms


HLS Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Shiller PE Ratio Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HLS Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSX:HLS vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Shiller PE Ratio falls into.


TSX:HLS
69GF Score
HLS Therapeutics Inc TSX:HLS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

HLS Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, HLS Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.042/133.5265*133.5265
=-0.042

Current CPI (Jun. 2026) = 133.5265.

HLS Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.010 101.765 -0.013
201612 -1.471 101.449 -1.936
201703 -0.030 102.634 -0.039
201706 -0.020 103.029 -0.026
201709 -0.030 103.345 -0.039
201712 -0.515 103.345 -0.665
201803 -0.246 105.004 -0.313
201806 -0.026 105.557 -0.033
201809 -0.938 105.636 -1.186
201812 0.027 105.399 0.034
201903 -0.187 106.979 -0.233
201906 -0.080 107.690 -0.099
201909 -0.079 107.611 -0.098
201912 -0.553 107.769 -0.685
202003 0.006 107.927 0.007
202006 -0.271 108.401 -0.334
202009 -0.066 108.164 -0.081
202012 -0.295 108.559 -0.363
202103 -0.189 110.298 -0.229
202106 -0.086 111.720 -0.103
202109 -0.076 112.905 -0.090
202112 -0.166 113.774 -0.195
202203 -0.139 117.646 -0.158
202206 -0.359 120.806 -0.397
202209 -0.187 120.648 -0.207
202212 -0.272 120.964 -0.300
202303 -0.246 122.702 -0.268
202306 -0.385 124.203 -0.414
202309 -0.284 125.230 -0.303
202312 -0.228 125.072 -0.243
202403 -0.257 126.258 -0.272
202406 -0.247 127.522 -0.259
202409 -0.203 127.285 -0.213
202412 -0.142 127.364 -0.149
202503 -0.201 129.181 -0.208
202506 -0.123 129.892 -0.126
202509 -0.166 130.287 -0.170
202512 -0.055 130.366 -0.056
202603 -0.096 132.262 -0.097
202606 -0.042 133.527 -0.042

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$3.70 is trading 15.5% below its estimated GF Value™ of C$4.38. GuruFocus considers HLS Therapeutics to be Modestly Undervalued.

Key valuation signals for TSX:HLS:

  • Shiller PE Ratio:
  • GF Value™: C$4.38 vs. price of C$3.70 (15.5% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
69GF Score

Get the complete analysis for TSX:HLS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$3.70
Price
C$4.38
GF Value